Stelara (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
As the first and only biologic targeting both cytokines interleukin (IL)-12 and IL-23, Stelara provides a new therapeutic option for children six years of age and older living with active psoriatic arthritis
Active psoriatic arthritis in...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Arthritis | Children | Drugs & Pharmacology | Food and Drug Administration (FDA) | Pediatrics | Psoriatic Arthritis | Rheumatology | Stelara